drugset / Trial / NCT01250210

Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control

NCT01250210 ↗

Phase 2 Completed 123 enrolled Agile Therapeutics
RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluate the adequacy of ovulation suppression, cycle control, and safety of three transdermal contraceptive delivery systems (TCDSs).

Timeline

Start
2007-09
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Levonorgestrel Small molecule 2.17 mg —
Subject Levonorgestrel Small molecule 2.6 mg —
Subject ethinyl estradiol Small molecule 1.28 mg —
Subject ethinyl estradiol Small molecule 1.92 mg —
Subject ethinyl estradiol Small molecule 2.3 mg —

Indications